121 related articles for article (PubMed ID: 721951)
1. Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.
Mansel-Jones D; Taylor T; Doyle E; Chasseaud LF; Darragh A; O'Kelly DA; Over H
J Clin Pharmacol; 1978; 18(11-12):544-8. PubMed ID: 721951
[TBL] [Abstract][Full Text] [Related]
2. Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
Assinder DF; Chasseaud LF; Taylor T
J Pharm Sci; 1977 Jun; 66(6):775-8. PubMed ID: 577507
[TBL] [Abstract][Full Text] [Related]
3. Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
Chasseaud LF; Darragh A; Doyle E; Lambe RF; Taylor T
J Pharm Sci; 1984 May; 73(5):699-701. PubMed ID: 6737249
[TBL] [Abstract][Full Text] [Related]
4. Plasma concentrations of isosorbide dinitrate after oral administration of a sustained-release formulation to human subjects.
Assinder DF; Chasseaud LF; Hunter JO; Jung RJ; Taylor T
Arzneimittelforschung; 1977; 27(1):156-8. PubMed ID: 576817
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
Chasseaud LF; Doyle E; Taylor T; Darragh A
Biopharm Drug Dispos; 1981; 2(3):273-81. PubMed ID: 7295884
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
Taylor T; O'Kelly DA; Major RM; Darragh A; Chasseaud LF
Arzneimittelforschung; 1978; 28(8):1426-8. PubMed ID: 582411
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.
Taylor T; Chasseaud LF; Doyle E; Darragh A; O'Kelly DA; Fitzgerald D
Biopharm Drug Dispos; 1980; 1(3):149-56. PubMed ID: 7448342
[TBL] [Abstract][Full Text] [Related]
8. Isosorbide dinitrate bioavailability, kinetics, and metabolism.
Straehl P; Galeazzi RL
Clin Pharmacol Ther; 1985 Aug; 38(2):140-9. PubMed ID: 4017416
[TBL] [Abstract][Full Text] [Related]
9. Quantitative determination of isosorbide dinitrate and two metabolites in plasma.
Chin DA; Prue DG; Michelucci J; Kho BT; Warner CR
J Pharm Sci; 1977 Aug; 66(8):1143-5. PubMed ID: 894502
[TBL] [Abstract][Full Text] [Related]
10. Isosorbide 5-mononitrate pharmacokinetics in humans.
Taylor T; Chasseaud LF; Major R; Doyle E; Darragh A
Biopharm Drug Dispos; 1981; 2(3):255-63. PubMed ID: 7295882
[TBL] [Abstract][Full Text] [Related]
11. Concentrations of the vasodilator isosorbide dinitrate and its metabolites in the blood of human subjects.
Chasseaud LF; Down WH; Grundy RK
Eur J Clin Pharmacol; 1975 Apr; 8(3-4):157-60. PubMed ID: 1233213
[TBL] [Abstract][Full Text] [Related]
12. Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Halkin H; Almog S; Friedman E
Isr J Med Sci; 1979 May; 15(5):448-50. PubMed ID: 447513
[TBL] [Abstract][Full Text] [Related]
13. A study into the mucosal absorption of isosorbide dinitrate at different intraoral sites.
Pimlott SJ; Addy M
Oral Surg Oral Med Oral Pathol; 1985 Feb; 59(2):145-8. PubMed ID: 3856798
[TBL] [Abstract][Full Text] [Related]
14. Plasma levels of isosorbide dinitrate and the isosorbide mononitrates after increasing doses of a retard preparation of isosorbide dinitrate.
Bogaert MG; Rosseel MT
Nouv Presse Med; 1980 Sep; 9(34 Suppl):2424-7. PubMed ID: 7422532
[TBL] [Abstract][Full Text] [Related]
15. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Niopas I; Daftsios AC; Nikolaidis N
Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic effects of isosorbide dinitrate vs nitroglycerin in patients with unstable angina.
Willis WH; Russell RO; Mantle JA; Ratshin RA; Rackley CE
Chest; 1976 Jan; 69(1):15-22. PubMed ID: 811427
[TBL] [Abstract][Full Text] [Related]
17. Use of isosorbide dinitrate saliva concentrations for biopharmaceutical investigations.
Laufen H; Schmid M; Leitold M
J Pharm Sci; 1983 May; 72(5):496-9. PubMed ID: 6864494
[TBL] [Abstract][Full Text] [Related]
18. Bioequivalence of a sustained-release isosorbide dinitrate formulation at steady-state.
Taylor T; Chasseaud LF; Major RM; Leaf FC; Bonn R; Darragh A; Lambe RF
Biopharm Drug Dispos; 1985; 6(2):119-29. PubMed ID: 4005392
[TBL] [Abstract][Full Text] [Related]
19. Improved method for the rapid determination of isosorbide dinitrate in human plasma and its application in pharmacokinetic studies.
Laufen H; Scharpf F; Bartsch G
J Chromatogr; 1978 Nov; 146(3):457-64. PubMed ID: 721922
[TBL] [Abstract][Full Text] [Related]
20. Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Tam SW; Sabolinski ML; Worcel M; Packer M; Cohn JN
Clin Pharmacokinet; 2007; 46(10):885-95. PubMed ID: 17854237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
